Browse UBA6

Summary
SymbolUBA6
Nameubiquitin-like modifier activating enzyme 6
Aliases FLJ10808; UBA6, ubiquitin-activating enzyme E1; UBE1L2; ubiquitin-activating enzyme E1-like 2; E1-L2; MOP-4; ......
Chromosomal Location4q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location -
Domain PF16191 Ubiquitin-activating enzyme E1 four-helix bundle
PF16190 Ubiquitin-activating enzyme E1 FCCH domain
PF09358 Ubiquitin fold domain
PF00899 ThiF family
PF10585 Ubiquitin-activating enzyme active site
Function

Activates ubiquitin by first adenylating its C-terminal glycine residue with ATP, and thereafter linking this residue to the side chain of a cysteine residue in E1, yielding a ubiquitin-E1 thioester and free AMP. Specific for ubiquitin, does not activate ubiquitin-like peptides. Differs from UBE1 in its specificity for substrate E2 charging. Does not charge cell cycle E2s, such as CDC34. Essential for embryonic development. Required for UBD/FAT10 conjugation. Isoform 2 may play a key role in ubiquitin system and may influence spermatogenesis and male fertility.

> Gene Ontology
 
Biological Process GO:0007611 learning or memory
GO:0007612 learning
GO:0007626 locomotory behavior
GO:0016358 dendrite development
GO:0021537 telencephalon development
GO:0021543 pallium development
GO:0021761 limbic system development
GO:0021764 amygdala development
GO:0021766 hippocampus development
GO:0030900 forebrain development
GO:0042787 protein ubiquitination involved in ubiquitin-dependent protein catabolic process
GO:0044708 single-organism behavior
GO:0050890 cognition
GO:0060996 dendritic spine development
Molecular Function GO:0004839 ubiquitin activating enzyme activity
GO:0008641 small protein activating enzyme activity
GO:0016874 ligase activity
GO:0016877 ligase activity, forming carbon-sulfur bonds
GO:0019780 FAT10 activating enzyme activity
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG hsa04120 Ubiquitin mediated proteolysis
Reactome R-HSA-1280218: Adaptive Immune System
R-HSA-983168: Antigen processing
R-HSA-983169: Class I MHC mediated antigen processing & presentation
R-HSA-168256: Immune System
R-HSA-392499: Metabolism of proteins
R-HSA-597592: Post-translational protein modification
R-HSA-8852135: Protein ubiquitination
R-HSA-8866652: Synthesis of active ubiquitin
Summary
SymbolUBA6
Nameubiquitin-like modifier activating enzyme 6
Aliases FLJ10808; UBA6, ubiquitin-activating enzyme E1; UBE1L2; ubiquitin-activating enzyme E1-like 2; E1-L2; MOP-4; ......
Chromosomal Location4q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between UBA6 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolUBA6
Nameubiquitin-like modifier activating enzyme 6
Aliases FLJ10808; UBA6, ubiquitin-activating enzyme E1; UBE1L2; ubiquitin-activating enzyme E1-like 2; E1-L2; MOP-4; ......
Chromosomal Location4q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of UBA6 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell logFC: -2.35; FDR: 0.04630 Resistant to T cell-mediated killing
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell logFC: -2.66; FDR: 0.02150 Resistant to T cell-mediated killing
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolUBA6
Nameubiquitin-like modifier activating enzyme 6
Aliases FLJ10808; UBA6, ubiquitin-activating enzyme E1; UBE1L2; ubiquitin-activating enzyme E1-like 2; E1-L2; MOP-4; ......
Chromosomal Location4q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of UBA6 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.0960.776
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.1350.924
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.2720.773
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.1780.658
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.480.807
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.2050.935
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.0960.827
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.1130.948
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.0170.993
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.5530.624
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-0.1130.943
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.030.688
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of UBA6 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 141705.9-5.91
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103033.3-33.30.231
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27737.45.51.90.66
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 01407.1-7.11
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27597.45.12.30.647
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.1011.10.36
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47250250.364
1329033130MelanomaallAnti-PD-1 (nivolumab) 38275.305.30.507
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22139.109.10.519
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolUBA6
Nameubiquitin-like modifier activating enzyme 6
Aliases FLJ10808; UBA6, ubiquitin-activating enzyme E1; UBE1L2; ubiquitin-activating enzyme E1-like 2; E1-L2; MOP-4; ......
Chromosomal Location4q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of UBA6. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolUBA6
Nameubiquitin-like modifier activating enzyme 6
Aliases FLJ10808; UBA6, ubiquitin-activating enzyme E1; UBE1L2; ubiquitin-activating enzyme E1-like 2; E1-L2; MOP-4; ......
Chromosomal Location4q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of UBA6. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by UBA6.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolUBA6
Nameubiquitin-like modifier activating enzyme 6
Aliases FLJ10808; UBA6, ubiquitin-activating enzyme E1; UBE1L2; ubiquitin-activating enzyme E1-like 2; E1-L2; MOP-4; ......
Chromosomal Location4q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of UBA6. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolUBA6
Nameubiquitin-like modifier activating enzyme 6
Aliases FLJ10808; UBA6, ubiquitin-activating enzyme E1; UBE1L2; ubiquitin-activating enzyme E1-like 2; E1-L2; MOP-4; ......
Chromosomal Location4q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of UBA6 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolUBA6
Nameubiquitin-like modifier activating enzyme 6
Aliases FLJ10808; UBA6, ubiquitin-activating enzyme E1; UBE1L2; ubiquitin-activating enzyme E1-like 2; E1-L2; MOP-4; ......
Chromosomal Location4q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between UBA6 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolUBA6
Nameubiquitin-like modifier activating enzyme 6
Aliases FLJ10808; UBA6, ubiquitin-activating enzyme E1; UBE1L2; ubiquitin-activating enzyme E1-like 2; E1-L2; MOP-4; ......
Chromosomal Location4q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting UBA6 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.